FDA Approves Merck’s Keytruda Combined With Seagen/Astellas’s Padcev For Advanced Urothelial Cancer
The FDA approved Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in combination with Astellas Pharma Inc (OTC:ALMPF) & Seagen Inc’s (NASDAQ:SGEN) Padcev (enfortumab vedotin-ejfv) locally…